Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$6.44 USD

6.44
1,528,959

-0.02 (-0.31%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $6.45 +0.01 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ADMA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for ADMA Biologics Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 51 87 51 56 27
Receivables 27 16 29 13 3
Notes Receivable 0 0 0 0 0
Inventories 173 163 125 82 53
Other Current Assets 5 5 4 3 3
Total Current Assets 257 270 209 154 86
Net Property & Equipment 54 58 51 42 32
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 10 0 0 0 0
Intangibles 4 5 5 6 7
Deposits & Other Assets 5 5 4 2 3
Total Assets 329 348 276 208 127
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 16 13 12 11 9
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 1 1 1 0 0
Accrued Expenses 33 25 17 8 4
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 50 39 30 20 14
Mortgages 0 0 0 0 0
Deferred Taxes/Income 2 2 2 2 2
Convertible Debt 0 0 0 0 0
Long-Term Debt 131 143 95 93 83
Non-Current Capital Leases 10 11 7 4 1
Other Non-Current Liabilities 2 2 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 194 196 135 119 101
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 641 630 553 429 291
Retained Earnings -506 -478 -412 -340 -265
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 135 152 141 88 26
Total Liabilities & Shareholder's Equity 329 348 276 208 127
Total Common Equity 135 152 141 88 26
Shares Outstanding 226.00 221.80 195.80 104.90 59.30
Book Value Per Share 0.60 0.69 0.72 0.84 0.44

Fiscal Year End for ADMA Biologics Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 51 74 63 69
Receivables NA 27 31 37 27
Notes Receivable NA 0 0 0 0
Inventories NA 173 163 162 164
Other Current Assets NA 5 5 5 4
Total Current Assets NA 257 274 266 264
Net Property & Equipment NA 54 55 56 57
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 10 0 0 0
Intangibles NA 4 4 4 4
Deposits & Other Assets NA 5 7 6 5
Total Assets NA 329 349 343 341
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 16 11 12 13
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 1 1 1 1
Accrued Expenses NA 33 30 29 23
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 50 42 42 37
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 2 2 2 2
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 131 142 140 144
Non-Current Capital Leases NA 10 10 10 10
Other Non-Current Liabilities NA 2 2 2
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 194 198 196 195
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 641 640 638 630
Retained Earnings NA -506 -489 -491 -485
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 135 151 147 146
Total Liabilities & Shareholder's Equity NA 329 349 343 341
Total Common Equity 0 135 151 147 146
Shares Outstanding 228.20 226.00 225.90 224.50 222.20
Book Value Per Share 0.00 0.60 0.67 0.65 0.66